Background illustration for clinical trials search

Vaccines Clinical Trials

Find clinical trials for vaccines. Search for vaccines clinical trials in different cities and states across the United States.

Filter

Post-op T-DM1 in HER-2+ Salivary Gland Carcinomas

for
Salivary Gland Cancer, HER2 Gene Mutation
Location: Boston MA, Commack NY, Uniondale NY, Harrison NY,
Sponsor: Dana-Farber Cancer Institute

Sex: All

Age: 18+

Code: NCT04620187

Phase 2, Recruiting

BRE-10: Biomarker Optimization of Neoadjuvant Therapy in Breast Cancer

for
Breast Cancer, HER2-positive Breast Cancer
Location: Chicago IL
Sponsor: University of Illinois at Chicago

Sex: All

Age: 18+

Code: NCT06441890

Phase 2, Recruiting

A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer

for
Gastroesophageal-junction Cancer, Monoclonal Antibody,
Location: Sayre PA, West Palm Beach FL, Pompano Beach FL,
Sponsor: Shanghai Henlius Biotech

Sex: All

Age: 18+

Code: NCT06532006

Phase 3, Recruiting

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

for
Advanced Solid Tumor, Advanced Malignant Neoplasm,
Location: Boston MA, New Haven CT, New York NY, Philadelphia PA,
Sponsor: PMV Pharmaceuticals, Inc

Sex: All

Age: 12+

Code: NCT04585750

Phase 1, Phase 2, Recruiting

Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors

for
Advanced HR+/HER2- Breast Cancer,
Location: Boston MA, New York NY, Montreal, Toronto,
Sponsor: Novartis Pharmaceuticals

Sex: All

Age: 18 - 70+

Code: NCT06726148

Phase 1, Phase 2, Recruiting

Interested in new trials?

Get alerts for new trials in your area by subscribing now

Subscriber Image

Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer

for
Advanced Breast Carcinoma,
Location: Houston TX
Sponsor: M.D. Anderson Cancer Center

Sex: Female

Age: 18+

Code: NCT04090567

Phase 2, Recruiting

Ivermectin in Combination With Balstilimab or Pembrolizumab in Patients With Metastatic Triple Negative Breast Cancer and HR+/HER2- Metastatic Breast Cancer

for
Anatomic Stage IV Breast Cancer AJCC v8,
Location: Los Angeles CA
Sponsor: Yuan Yuan

Sex: All

Age: 18+

Code: NCT05318469

Phase 1, Phase 2, Recruiting

Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer

for
Locoregional Recurrence,
Location: Boston MA, New York NY, New Brunswick NJ, Hershey PA,
Sponsor: Oana Danciu

Sex: All

Age: 18+

Code: NCT05467891

Phase 2, Recruiting

Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer

for
Breast Cancer, Breast Neoplasm, Breast Cancer Female,
Location: Houston TX
Sponsor: Baylor Breast Care Center

Sex: All

Age: 18+

Code: NCT05020860

Phase 2, Recruiting

Adaptive De-intensified Radiotherapy Using Circulating Tumor DNA in HPV- Associated Oropharyngeal Cancer

for
Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8,
Location: Columbus OH
Sponsor: Ohio State University Comprehensive Cancer Center

Sex: All

Age: 18+

Code: NCT06323460

Phase 2, Recruiting

Turkey Tail Mushroom for Treating Post-Menopausal Women With HER2-Negative ER-Positive Breast Cancer Undergoing Surgery

for
Estrogen Receptor-Positive Breast Carcinoma,
Location: Scottsdale AZ
Sponsor: Mayo Clinic

Sex: Female

Age: 18+

Code: NCT06450873

Phase 2, Recruiting

A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors

for
HER2-positive Advanced Solid Tumor
Location: Boston MA, Shirley NY, Lake Success NY, New York NY,
Sponsor: DualityBio Inc.

Sex: All

Age: 18+

Code: NCT05150691

Phase 1, Phase 2, Recruiting

Immune Function and Response to Vaccination After Cancer Therapy in Pediatric Patients

for
Pediatric Cancer
Location: Charlotte NC
Sponsor: Wake Forest University Health Sciences

Sex: All

Age: 2 - 21

Code: NCT04948619

Phase 2, Recruiting
New

Multitargeted Recombinant Ad5 PSA/MUC-1/Brachyury-Based Immunotherapy (TriAdeno) Vaccine With IL-15 Superagonist N-803 in Participants With Clinically Localized Prostate Cancer Undergoing Active Surveillance

for
Adenocarcinoma, Prostate Cancer, Neoplasms, Carcinoma,
Location: Bethesda MD
Sponsor: National Cancer Institute (NCI)

Sex: Male

Age: 18 - 70+

Code: NCT07574541

Phase 2, Recruiting
New

Universal Immunization to Fortify Immunotherapy Efficacy and Response

for
Stage 4 NSCLC
Location: Gainesville FL
Sponsor: University of Florida

Sex: All

Age: 18+

Code: NCT07597070

Phase 2, Recruiting
New

Impact of Egg-Based and Cell-Based Vaccine Platforms on Immune Responses to Repeated Influenza Vaccination

for
Immunology
Location: Columbia MO
Sponsor: University of Missouri-Columbia

Sex: All

Age: 18+

Code: NCT07910266

Phase 4, Recruiting
New

TMV Vaccine Alone or With Toripalimab-tpzi for Recurrent Head and Neck Squamous Cell Carcinoma

for
Squamous Cell Carcinoma of Head and Neck,
Location: Houston TX
Sponsor: Metaclipse Therapeutics Corporation

Sex: All

Age: 18+

Code: NCT07898124

Phase 1, Recruiting

ADAGiO: Adoptive Cellular Therapy for the TreAtment of Recurrent OliGodendrogliOma (OG) Adult Patients

for
Recurrent Oligodendroglioma, Progressive Oligodendroglioma
Location: Gainesville FL
Sponsor: University of Florida

Sex: All

Age: 18 - 70+

Code: NCT06254326

Phase 1, Recruiting

Adolescents' Response to Hepatitis B Vaccine Booster Dose

for
Hepatitis B
Location: Houston TX
Sponsor: Baylor College of Medicine

Sex: All

Age: 16 - 19

Code: NCT01341275

Recruiting

A Feasibility Study Utilizing Immune Recall to Increase Response to Checkpoint Therapy

for
Melanoma
Location: Durham NC
Sponsor: Duke University

Sex: All

Age: 18+

Code: NCT05077137

Phase 1, Recruiting

What vaccine clinical trials are studying now

New flu vaccines. Moderna's mFlusiva, approved August 5, 2026 for adults 50 and older, is the first mRNA flu vaccine. In its Phase 3 trial it prevented about 27 percent more flu cases than a standard dose vaccine, with more short term side effects. Flu vaccine studies, including human challenge trials, are listed on our influenza clinical trials page.

Vaccines in pregnancy. Vaccinating a mother so antibodies pass to the baby is one of the most active areas of research. A Phase 3 trial of a group B streptococcus vaccine, a leading cause of serious infection in newborns, is recruiting pregnant participants at 120 US sites.

Pneumococcal and other bacterial vaccines. Next generation vaccines that cover more strains of the bacteria behind pneumonia and meningitis, tested against the vaccines in use today. Two pneumococcal vaccine studies are enrolling healthy adults 18 to 75 who have never had a pneumococcal vaccine.

RSV vaccines. Combination and revaccination studies, covered on our RSV vaccine clinical trials page. Studies of new flu and RSV vaccines for adults 60 and older are enrolling now.

Cancer vaccines. These do not prevent cancer; they teach the immune system to attack a cancer that is already there. Intismeran, made for each patient from up to 34 mutations in their own tumor, met its main goal in a Phase 3 melanoma trial in August 2026 but is not yet approved. Smaller studies test vaccines for HER2 positive breast cancer, liver cancer, and HPV related cancers; see our melanoma and breast cancer pages.

COVID-19. Updated formulas are approved each season; the 2026 to 2027 mRNA formula is approved for adults 65 and older and for people 5 to 64 with a condition that raises their risk. One study is testing a COVID-19 vaccine given during an active infection, for people 12 and older who tested positive within the past 5 days and have a risk factor for severe illness; it measures the immune response and is not a treatment for the current illness. Studies of COVID-19 and long COVID are on our COVID-19 page.

Vaccines for infections that have none yet. There is still no approved vaccine against Epstein-Barr virus, the cause of mono, or against C. difficile, a common hospital infection. A study of an EBV vaccine is enrolling healthy adults 18 to 30, and C. diff vaccine studies are enrolling adults 65 and older who have frequent contact with healthcare but have never had the infection.

Human challenge studies. Healthy adults receive a vaccine or placebo, then a controlled dose of a virus such as influenza, in a monitored setting. They answer in weeks what field trials take seasons to show.

Article preview image

65 or older? Read our guide: Not All Flu Vaccines Work the Same After 65: Which to Choose and When to Get It

Not All Flu Vaccines Work the Same After 65: Which to Choose and When to Get It

How vaccine trials differ from drug trials

Who can participate in vaccine clinical trials?

Do vaccine trial participants get paid?

How to enroll in a vaccine clinical trial